Fibroscan Study in HCC
Not Applicable
Active, not recruiting
- Conditions
- Child's A to C CirrhosisConfirmed Diagnosis of Hepatocellular CarcinomaPatients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery
- Interventions
- Other: Fibroscan
- Registration Number
- NCT01796145
- Lead Sponsor
- Chinese University of Hong Kong
- Brief Summary
In patients with HCC undergoing therapy 1. We aim to determine the prognostic significance of liver stiffness in patients with HCC 2. We aim to determine the rate and severity of complications of treatment and its association with liver stiffness in patients with HCC
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 207
Inclusion Criteria
-
Clinical diagnosis of HCC
-
Patients who are scheduled to undergo therapy, either TACE systemic therapy or surgery
- For TACE cohort, patients undergoing first cycle TACE are eligible.
- For systemic therapy cohort, patients undergoing first-line systemic therapy are eligible.
- For surgery cohort, patient undergoing surgery are eligible.
-
Prior surgery or loco-ablative therapy (e.g. Radiofrequency ablation, microwave, percutaneous ethanol injection) is allowed
-
Child's A to Child's C liver function
Read More
Exclusion Criteria
- ECOG performance status > 2
- Poorly controlled ascites
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Systemic Therapy Fibroscan - TACE Fibroscan - Surgery Fibroscan -
- Primary Outcome Measures
Name Time Method Overall survival 3 years
- Secondary Outcome Measures
Name Time Method Liver stiffness (kPa) 2 years Rate and grade of treatment complications 2 years
Trial Locations
- Locations (1)
Department of Clinical Oncology, Prince of Wales Hospital
ðŸ‡ðŸ‡°Hong Kong, Hong Kong